OpRegen for geographic atrophy

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Nov 2022: Trial registered, NCT05626114
  2. 23 Mar 2023: Trial started, NCT05626114

The trials

NCT05626114: A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

State
Under way
Phase
Phase 2
People
60 planned
Started
23 Mar 2023
Primary completion
1 Mar 2031
Arms
OpRegen
Results
None posted
  1. 23 Nov 2022: Trial registered
  2. 23 Mar 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.